



IMRICOR'S PRODUCTS TO OPERATE WITH GE HEALTHCARE MRI SYSTEMS

Highlights:

- GE HealthCare and Imricor signed an MSA to make Imricor products work with GE HealthCare MRI systems
- GE HealthCare will pay Imricor to develop the needed hardware and software interfaces
- Imricor's NorthStar 3D mapping system will operate with GE HealthCare MRI systems
- Upon the addition of GE HealthCare, Imricor's products will operate with the vast majority of 1.5T MRI systems sold in Imricor's target markets

23 April 2023 – Minneapolis, MN United States (**24 April 2023** – Melbourne, Australia) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that it has entered into a Master Services Agreement (MSA) with GE Precision Healthcare LLC (GE HealthCare), following the Memorandum of Understanding the two companies executed in January 2023.

Under the terms of the MSA, GE HealthCare will pay Imricor to develop the hardware and software interfaces required to make Imricor's real-time iCMR cardiac ablation solutions operate with GE HealthCare MRI systems. The deliverables for payment are milestone based, with certain compatibility test reports being the final deliverable. Imricor will retain ownership of all technology and equipment developed during the project.

The hardware interface will connect Imricor's Advantage-MR EP Recorder/Stimulator to GE HealthCare's 1.5T MRI platform, such that Imricor's catheters and other devices may be recognised and actively tracked by GE HealthCare MRI scanners. Similarly, the software interface will connect Imricor's NorthStar 3D mapping system to GE HealthCare MRI scanners.

The MSA is effective as of April 20, 2023, and has an initial term ending December 31, 2026. The hardware and software interface development projects are anticipated to be completed in Q4 2023.

Imricor's Chair and CEO, Steve Wedan, commented: *"We are thrilled that GE HealthCare is working with us to deliver real-time iCMR cardiac ablations on their MRI platform. Upon the addition of GE HealthCare, Imricor's technology will operate with the vast majority of 1.5T MRI systems sold in our target markets today. This is a huge step forward and expands our potential market significantly. The fact that GE HealthCare is paying Imricor for the required development work speaks, I think, to their commitment to the field and belief in the future growth potential of iCMR interventions."*

"This development is also another major step forward for our NorthStar 3D mapping system, as we execute our plan to make NorthStar the centre of every iCMR program."

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.



Media and Investor Relations Contact:

Simon Hinsley
simon@nwrcommunications.com.au
+61 401 909 653

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.